Dyne Therapeutics Inc.

6.51-0.5000-7.13%Vol 213.34K1Y Perf -68.61%
Jun 28th, 2022 16:00 DELAYED
BID5.11 ASK7.97
Open6.98 Previous Close7.01
Pre-Market- After-Market6.51
 - -  - -%
Target Price
27.75 
Analyst Rating
Strong Buy 1.00
Potential %
326.27 
Finscreener Ranking
★★★★★     61.40
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★     55.93
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★+     55.79
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
11.87 
Earnings Rating
Strong Buy
Market Cap336.26M 
Earnings Date
4th Aug 2022
Alpha-0.07 Standard Deviation0.16
Beta0.92 

Today's Price Range

6.397.17

52W Range

4.3022.92

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
21.91%
1 Month
42.48%
3 Months
-22.11%
6 Months
-43.33%
1 Year
-68.61%
3 Years
-
5 Years
-16.65%
10 Years
-

TickerPriceChg.Chg.%
DYN6.51-0.5000-7.13
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
13.90
14.80
0.08
0.10
-1 556.50
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
39.40
1.60
18.60
-23.60
-14.58
RevenueValueIndustryS&P 500US Markets
0.00
0.00
25.32
36.24
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.88-0.6921.59
Q04 2021-0.99-1.00-1.01
Q03 2021-0.65-0.83-27.69
Q02 2021-0.55-0.58-5.45
Q01 2021-0.60-0.5016.67
Q04 2020-0.38-0.64-68.42
Q03 2020-0.88-2.01-128.41
Q04 2017-0.330.01103.03
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.8113.83Positive
9/2022 QR-0.8812.00Positive
12/2022 FY-3.3614.07Positive
12/2023 FY-3.7110.17Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.81
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume213.34K
Shares Outstanding51.65K
Shares Float31.41M
Trades Count1.29K
Dollar Volume1.40M
Avg. Volume212.48K
Avg. Weekly Volume247.72K
Avg. Monthly Volume226.18K
Avg. Quarterly Volume163.55K

Dyne Therapeutics Inc. (NYSE: DYN) stock closed at 7.01 per share at the end of the most recent trading day (a 2.64% change compared to the prior day closing price) with a volume of 132.84K shares and market capitalization of 336.26M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Dyne Therapeutics Inc. CEO is Joshua T. Brumm.

The one-year performance of Dyne Therapeutics Inc. stock is -68.61%, while year-to-date (YTD) performance is -41.04%. DYN stock has a five-year performance of -16.65%. Its 52-week range is between 4.3 and 22.92, which gives DYN stock a 52-week price range ratio of 11.87%

Dyne Therapeutics Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 1.05, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 3.50, a PEG ratio of 2.32, a ROA of -36.36%, a ROC of -36.69% and a ROE of -39.25%. The company’s profit margin is -14.58%, its EBITDA margin is 18.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Dyne Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.81 for the next earnings report. Dyne Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Dyne Therapeutics Inc. is Strong Buy (1), with a target price of $27.75, which is +326.27% compared to the current price. The earnings rating for Dyne Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Dyne Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Dyne Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.30, ATR14 : 0.60, CCI20 : 178.10, Chaikin Money Flow : 0.13, MACD : 0.16, Money Flow Index : 85.38, ROC : 42.19, RSI : 64.12, STOCH (14,3) : 95.02, STOCH RSI : 1.00, UO : 58.34, Williams %R : -4.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Dyne Therapeutics Inc. in the last 12-months were: Jonathan McNeill (Sold 1 755 shares of value $24 451 ), Joshua T. Brumm (Sold 11 393 shares of value $156 855 ), Oxana Beskrovnaya (Sold 2 137 shares of value $29 004 ), Richard William Scalzo (Sold 1 167 shares of value $16 344 ), Susanna High (Sold 3 216 shares of value $48 885 ), Wildon Farwell (Sold 6 257 shares of value $53 669 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

CEO: Joshua T. Brumm

Telephone: +1 781 786-8230

Address: 830 Winter Street, Waltham 02451, MA, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

News

Stocktwits